Soleno Therapeutics, Inc. (NASDAQ:SLNO) Holdings Boosted by Deutsche Bank AG

Deutsche Bank AG raised its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 44.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 119,455 shares of the company's stock after acquiring an additional 36,971 shares during the period. Deutsche Bank AG owned 0.28% of Soleno Therapeutics worth $5,370,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Corebridge Financial Inc. raised its holdings in Soleno Therapeutics by 2.9% in the 4th quarter. Corebridge Financial Inc. now owns 12,720 shares of the company's stock valued at $572,000 after acquiring an additional 357 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in Soleno Therapeutics by 24.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company's stock valued at $120,000 after acquiring an additional 522 shares during the last quarter. AlphaQuest LLC raised its holdings in Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock valued at $32,000 after acquiring an additional 658 shares during the last quarter. US Bancorp DE acquired a new position in Soleno Therapeutics in the 4th quarter valued at $34,000. Finally, Alliancebernstein L.P. raised its holdings in Soleno Therapeutics by 3.5% in the 4th quarter. Alliancebernstein L.P. now owns 23,810 shares of the company's stock valued at $1,070,000 after acquiring an additional 800 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Soleno Therapeutics

In other news, CEO Bhatnagar Anish sold 699,095 shares of Soleno Therapeutics stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the sale, the chief executive officer now owns 577,076 shares of the company's stock, valued at approximately $39,021,879.12. The trade was a 54.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Patricia C. Hirano sold 128,653 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $68.32, for a total value of $8,789,572.96. Following the sale, the insider now directly owns 55,789 shares in the company, valued at approximately $3,811,504.48. The trade was a 69.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 942,672 shares of company stock valued at $64,058,781. Insiders own 12.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SLNO. HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of Soleno Therapeutics in a research note on Tuesday, April 15th. Stifel Nicolaus boosted their price objective on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, March 28th. Piper Sandler boosted their price objective on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Cantor Fitzgerald boosted their price objective on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Guggenheim boosted their price objective on shares of Soleno Therapeutics from $81.00 to $97.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $106.78.

Soleno Therapeutics Price Performance

NASDAQ SLNO traded up $3.00 during trading hours on Friday, hitting $76.89. The company had a trading volume of 474,984 shares, compared to its average volume of 749,080. The firm's 50 day moving average is $68.88 and its 200 day moving average is $55.71. The company has a market capitalization of $3.87 billion, a price-to-earnings ratio of -23.16 and a beta of -2.67. Soleno Therapeutics, Inc. has a fifty-two week low of $36.93 and a fifty-two week high of $80.99.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.19. On average, equities analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.